PLYX - Polaryx Therapeutics, Inc. Common Stock News

Discover

PLYX

Polaryx Therapeutics, Inc. Common Stock

2.09

1 x 2.08

1 x 2.12

bid

ask

0.01

0.48%

1 @ 04:00 PM

2.13 +0.04 (2.15%)

Ytd	-94.03%
1y	-94.03%

2.07

day range

2.16

1.86

52 week range

48.91

Open	2.13	Prev Close	2.10	Low	2.07	High	2.16	Mkt Cap	104.18M
Vol	82.77K	Avg Vol	196.29K	EPS	-0.20	P/E	-10.72	Forward P/E	N/A
Beta	N/A	Short Ratio	N/A	Inst. Own	N/A	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	N/A	50-d Avg	2.32	200-d Avg	4.28	1yr Est	0.00

PLYX News

benzinga.com

This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

Wall Street analysts changed outlook on top names. Check analyst ratings page for all changes. See w

benzinga.com

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

globenewswire.com

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support

PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”

benzinga.com

12 Health Care Stocks Moving In Thursday's After-Market Session

globenewswire.com

Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards

Company selected as Best Pediatric Lysosomal Storage Disease Therapeutics and Rare Neurodegenerative

globenewswire.com

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Famil

PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stag

globenewswire.com

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evalua

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clini

globenewswire.com

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Company selected as a Diamond honoree for Excellence in Pediatric Care Company selected as a Diamond

benzinga.com

12 Health Care Stocks Moving In Monday's Intraday Session

globenewswire.com

Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

PARAMUS, NJ, April 01, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinica

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

globenewswire.com

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Cer

PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinica

benzinga.com

12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Thursday's Intraday Session

globenewswire.com

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Pat

PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinica

globenewswire.com

Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric

PARAMUS, NJ, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage

feeds.benzinga.com

What's Going On With Polaryx Therapeutics Stock Wednesday?

Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical developmen

benzinga.com

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

globenewswire.com

Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial

PARAMUS, NJ, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

globenewswire.com

Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™

PARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage

globenewswire.com

Polaryx Therapeutics Welcomes New Members of the Board of Directors

PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX) a clinical-

globenewswire.com

Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Compan

Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in th

globenewswire.com

Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “P

PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a c

globenewswire.com

Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq

PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a c

seekingalpha.com

Polaryx Therapeutics Seeks Direct Listing For Shareholders

Polaryx Therapeutics is pursuing a direct listing with no proceeds to the company and no new institu